Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin

Oncotarget

Volumn 5, Issue 9, 2014, Pages 2778-2791

  Maleki Vareki, Saman ^a,b   Rytelewski, Mateusz ^a,b   Figueredo, Rene ^b   Chen, Di ^a   Ferguson, Peter J ^a,b   Vincent, Mark ^a,b   Min, Weiping ^a   Zheng, Xiufen ^a   Koropatnick, James ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

BRCA2; CISPLATIN; IDO; OLAPARIB; PARP; RADIATION

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; COMPLEMENTARY DNA; INDOLEAMINE 2,3 DIOXYGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BRCA2 PROTEIN, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG RESISTANCE; G2 PHASE CELL CYCLE CHECKPOINT; GAMMA RADIATION; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOCOMPETENT CELL; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR CELL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; ENZYMOLOGY; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; RADIATION DOSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRCA2 PROTEIN; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS; PHTHALAZINES; PIPERAZINES; RADIATION TOLERANCE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84901236250     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Meads MB, Gatenby RA and Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nature reviews Cancer. 2009; 9(9):665-674.
2. Gottesman MM. Mechanisms of cancer drug resistance. Annual review of medicine. 2002; 53:615-627.
3. Zahreddine H and Borden KL. Mechanisms and insights into drug resistance in cancer. Frontiers in pharmacology. 2013; 4:28.
4. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM. Targeting multidrug resistance in cancer. Nature reviews Drug discovery. 2006; 5(3):219-234.
5. Munn DH and Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends in immunology. 2013; 34(3):137-143.
6. Godin-Ethier J, Hanafi LA, Piccirillo CA and Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(22):6985-6991.
7. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC and Muller AJ. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer discovery. 2012; 2(8):722-735.
8. Zheng X, Koropatnick J, Li M, Zhang X, Ling F, Ren X, Hao X, Sun H, Vladau C, Franek JA, Feng B, Urquhart BL, Zhong R, Freeman DJ, Garcia B and Min WP. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006; 177(8):5639-5646.
9. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL, Jr. and Mellor AL. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002; 297(5588):1867-1870.
10. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, Descamps P, Gamelin E, Gascan H, Hebbar M and Jeannin P. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007; 110(13):4319-4330.
11. Sharma MD, Huang L, Choi JH, Lee EJ, Wilson JM, Lemos H, Pan F, Blazar BR, Pardoll DM, Mellor AL, Shi H and Munn DH. An inherently bifunctional subset of foxp3(+) T helper cells is controlled by the transcription factor eos. Immunity. 2013; 38(5):998-1012.
12. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nature immunology. 2011; 12(9):870-878.
13. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature medicine. 2011; 17(9):1094-1100.
14. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ and Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012; 1(9):1460-1468.
15. Khan JA, Forouhar F, Tao X and Tong L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert opinion on therapeutic targets. 2007; 11(5):695-705.
16. Javle M and Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. British journal of cancer. 2011; 105(8):1114-1122.
17. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y and Gilks CB. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(4):783-791.
18. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nature reviews Cancer. 2012; 12(12):801-817.
19. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J and Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. The New England journal of medicine. 2012; 366(15):1382-1392.
20. Chen Y, Zhang L and Hao Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Archives of gynecology and obstetrics. 2013.
21. Karanikas V, Zamanakou M, Kerenidi T, Dahabreh J, Hevas A, Nakou M, Gourgoulianis KI and Germenis AE. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer biology&therapy. 2007; 6(8):1258-1262.
22. Zhang G, Liu WL, Zhang L, Wang JY, Kuang MH, Liu P, Lin YH, Dai SQ and Du J. Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma. Clinical&developmental immunology. 2011; 2011:384726.
23. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML and Lu B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(10):3033-3042.
24. Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, Klein EA and Almasan A. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PloS one. 2013; 8(4):e60408.
25. Surjana D, Halliday GM and Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. Journal of nucleic acids. 2010; 2010.
26. Rytelewski M, Ferguson PJ, Maleki Vareki S, Figueredo R, Vincent M and Koropatnick J. Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality". Molecular therapy Nucleic acids. 2013; 2:e78.
27. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T and Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature medicine. 2003; 9(10):1269-1274.
28. Kai S, Goto S, Tahara K, Sasaki A, Kawano K and Kitano S. Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. Journal of experimental therapeutics&oncology. 2003; 3(6):336-345.
29. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A and Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. The Journal of experimental medicine. 1999; 189(9):1363-1372.
30. Curtin NJ and Szabo C. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Molecular aspects of medicine. 2013.
31. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-917.
32. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-921.
33. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine. 2009; 361(2):123-134.
34. Begg AC, Stewart FA and Vens C. Strategies to improve radiotherapy with targeted drugs. Nature reviews Cancer. 2011; 11(4):239-253.
35. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E and Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature medicine. 2005; 11(3):312-319.
36. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Molecular oncology. 2011; 5(4):387-393.
37. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, Tjornelund J, Dawson KM, Dupuis M and Duchosal MA. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 2009; 113(14):3276-3286.
38. Hasmann M and Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer research. 2003; 63(21):7436-7442.
39. Garten A, Petzold S, Korner A, Imai S and Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends in endocrinology and metabolism: TEM. 2009; 20(3):130-138.
40. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C, Mottis A, Jo YS, Viswanathan M, Schoonjans K, Guarente L and Auwerx J. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell. 2013; 154(2):430-441.
41. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N and Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008; 451(7182):1116-1120.
42. Jassem J. Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer. The lancet oncology. 2001; 2(6):335-342.
43. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, Wedge SR and Stratford IJ. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Molecular cancer therapeutics. 2011; 10(10):1949-1958.
44. Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N, Navarro B, Ichim TE, Urquhart B and Min W. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. International journal of cancer Journal international du cancer. 2013; 132(4):967-977.
45. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD and Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of experimental medicine. 2013; 210(7):1389-1402.
46. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nature reviews Cancer. 2007; 7(11):834-846.